Dr. Reddy's Laboratories introduces Desloratadine ODT in the US market

Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Desloratadine ODT (2.5 mg & 5 mg), a bioequivalent generic version of Clarinex® Reditabs® (desloratadine) in the US market on January 24, 2013. Dr. Reddy's ANDA for Desloratadine ODT is approved by the United States Food & Drug Administration (USFDA).

The Clarinex® Reditabs® brand had U.S. sales of approximately $5.3 Million for the most recent twelve months ending November 2012 according to IMS Health*.

Dr. Reddy's Desloratadine ODT 2.5 mg & 5 mg are available in unit dose packages of 30 (5x6).


Dr. Reddy's Laboratories Ltd.

Posted in: Pharmaceutical News

Tags: , ,



The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment